Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 06 2023 - 4:10PM
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal
RNA-targeted genetic therapies for rare diseases, today announced
that it will present at the Oppenheimer 33rd Annual Healthcare
Conference on Monday, March 13th at 12:00 PM ET.
A live webcast of the presentation and a replay of
the presentation will be available on the Company’s website at
https://investors.eloxxpharma.com/events-presentations.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is engaged in the science of
ribosome modulation, leveraging its innovative
TURBO-ZM™ chemistry technology platform in an effort to
develop novel Ribosome Modulating Agents (RMAs) and its library of
Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead
investigational product candidate, ELX-02, is a small molecule drug
candidate designed to restore production of full-length functional
proteins. ELX-02 is in Phase 2 clinical development for the
treatment of Alport syndrome in patients with nonsense mutations.
Eloxx also has preclinical programs focused on select rare
diseases, including inherited diseases, cancer caused by nonsense
mutations, kidney diseases, including autosomal dominant polycystic
kidney disease, as well as rare ocular genetic disorders.
For more information, please visit www.eloxxpharma.com.
Contact
InvestorsJohn
Woolfordjohn.woolford@westwicke.com443.213.0506
MediaLaureen Cassidylaureen@outcomescg.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jul 2023 to Jul 2024